

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 5, 2024

**ANNOVIS BIO, INC.**  
(Exact Name of Registrant as Specified in Charter)

Delaware  
(State or Other Jurisdiction  
of Incorporation)

001-39202  
(Commission  
File Number)

26-2540421  
(I.R.S. Employer  
Identification No.)

101 Lindenwood Drive, Suite 225  
Malvern, PA 19355  
(Address of Principal Executive Offices, and Zip Code)

(484) 875-3192  
Registrant's Telephone Number, Including Area Code

Not Applicable  
(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.0001 per share	ANVS	New York Stock Exchange

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01 Regulation FD Disclosure**

On June 5, 2024, Annovis Bio, Inc. issued a press release scheduling an investor webcast on June 11, 2024 at 4:30pm ET. The press release is furnished as Exhibit 99.1 hereto.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
<a href="#">99.1</a>	<a href="#">Press Release Dated June 5, 2024</a>
104	Cover Page Interactive Data File

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ANNOVIS BIO, INC.**

Date: June 5, 2024

By: /s/ Maria Maccellini

Name: Maria Maccellini

Title: President and Chief Executive Officer

---

**Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast**

**MALVERN, Pa. June 5, 2024** -- Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), today announced that it will host an investor webcast to discuss recent developments and future plans for its lead drug candidate, Buntanetap.

**Investor Call Details:**

- **Date and Time:** June 11, 2024, 4:30pm ET.
- **Register Today:**  
[https://zoom.us/webinar/register/WN\\_Ev\\_1s7l2RUKmIQJNdko5iA](https://zoom.us/webinar/register/WN_Ev_1s7l2RUKmIQJNdko5iA)

**Topics to Be Covered:**

- Recent advancements in the development of Buntanetap.
- Strategic plans for upcoming clinical trials.
- Overview of the company’s progress and future direction.

**Register Today:** Investors and interested parties are encouraged to register for the webcast in advance. To register, please visit [https://zoom.us/webinar/register/WN\\_Ev\\_1s7l2RUKmIQJNdko5iA](https://zoom.us/webinar/register/WN_Ev_1s7l2RUKmIQJNdko5iA) and complete the registration form.

**About Buntanetap:** Buntanetap (formerly known as Posiphen or ANVS401) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. By improving synaptic transmission, axonal transport, and reducing neuroinflammation, Buntanetap aims to reverse neurodegeneration in AD, PD, and other neurodegenerative diseases.

**About Annovis Bio Inc.:** Headquartered in Malvern, Pennsylvania, Annovis Bio Inc. is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit [Annovis Bio's website](#) and follow us on [LinkedIn](#) and X.

---

## **Forward Looking Statements**

This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The Company advises caution in reliance on forward-looking statements. Forward-looking statements include, without limitation, the Company's plans related to clinical trials. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those implied by forward-looking statements, including regarding patient enrollment, the effectiveness of Buntanetap and the timing, effectiveness, and anticipated results of the Company's clinical trials evaluating the efficacy, safety and tolerability of buntanetap. See also additional risk factors set forth in the Company's periodic filings with the SEC, including, but not limited to, those risks and uncertainties listed in the section entitled "Risk Factors," in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC. All forward-looking statements in this press release are based on information available to the Company as of the date of this filing. The Company expressly disclaims any obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

## **Contacts**

### **Annovis Bio, Inc.**

101 Lindenwood Drive  
Suite 225  
Malvern, PA 19355  
[www.annovisbio.com](http://www.annovisbio.com)

### **Investor Contact**

Scott McGowan  
InvestorBrandNetwork (IBN)  
Phone: 310.299.1717  
[IR@annovisbio.com](mailto:IR@annovisbio.com)  
[Investor Website](#)

---